Literature DB >> 20817227

A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer.

Jeanne Carter1, Yukio Sonoda, Raymond E Baser, Leigh Raviv, Dennis S Chi, Richard R Barakat, Alexia Iasonos, Carol L Brown, Nadeem R Abu-Rustum.   

Abstract

OBJECTIVE: To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery.
METHODS: Seventy-one women who were consented for radical trachelectomy (RT) or radical hysterectomy (RH) were enrolled preoperatively in this 2-year study; 52 women (33 RT; 19 RH) were actively followed. Patients completed self-report surveys composed of 4 empirical measures in addition to exploratory items. Data analyses for the 2 years of prospective data are presented.
RESULTS: At preoperative assessment, women choosing RH reported greater concern about cancer recurrence (x=7.27 [scale from 0 to 10]) than women choosing RT (x=5.66) (P=0.008). Forty-eight percent undergoing RH compared to 8.6% undergoing RT reported having adequate "time to complete childbearing" (P<0.001). Both groups demonstrated scores suggestive of depression (based on the CES-D scale) and distress (based on the IES scale) preoperatively; over time, however, CES-D and IES scores generally improved. Scores on the Female Sexual Functioning Inventory (FSFI) for the total sample were below the mean cut-off (26.55), suggestive of sexual dysfunction; however, the means increased from 16.79 preoperatively to 23.78 by 12 months and 22.20 at 24 months.
CONCLUSION: Measurements of mood, distress, sexual function, and QOL did not differ significantly by surgical type, and instead reflect the challenges faced by young cervical cancer patients treated by RT or RH without adjuvant treatment. Points of vulnerability were identified in which patients may benefit from preoperative consultation or immediate postoperative support. Overall, patients improved during the first year, reaching a plateau between Year-1 and Year-2, which may reflect a new level of functioning in survivorship.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20817227      PMCID: PMC4847134          DOI: 10.1016/j.ygyno.2010.07.016

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women.

Authors:  J H Shepherd; C Spencer; J Herod; T E J Ind
Journal:  BJOG       Date:  2006-06       Impact factor: 6.531

2.  Vaginal radical trachelectomy: an update.

Authors:  Marie Plante
Journal:  Gynecol Oncol       Date:  2008-08-27       Impact factor: 5.482

3.  Randomized trial of peer counseling on reproductive health in African American breast cancer survivors.

Authors:  Leslie R Schover; Rosell Jenkins; Dawen Sui; Jennifer Harned Adams; Michelle S Marion; Karen Eubanks Jackson
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

4.  Reproductive concerns of women treated with radical trachelectomy for cervical cancer.

Authors:  Jeanne Carter; Yukio Sonoda; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2006-12-22       Impact factor: 5.482

5.  A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?

Authors:  Yukio Sonoda; Nadeem R Abu-Rustum; Mary L Gemignani; Dennis S Chi; Carol L Brown; Elizabeth A Poynor; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

6.  Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

Authors:  Bradley J Monk; Helen Q Huang; David Cella; Harry J Long
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

7.  Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].

Authors:  Edward L Nelson; Lari B Wenzel; Kathryn Osann; Aysun Dogan-Ates; Nissa Chantana; Astrid Reina-Patton; Amanda K Laust; Kevin P Nishimoto; Alexandra Chicz-DeMet; Nefertiti du Pont; Bradley J Monk
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 8.  Fertility preserving surgery for carcinoma of the cervix.

Authors:  David A Milliken; John H Shepherd
Journal:  Curr Opin Oncol       Date:  2008-09       Impact factor: 3.645

9.  Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.

Authors:  Margaret H Einstein; Kay J Park; Yukio Sonoda; Jeanne Carter; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2008-10-29       Impact factor: 5.482

10.  Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.

Authors:  John P Diaz; Yukio Sonoda; Mario M Leitao; Oliver Zivanovic; Carol L Brown; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2008-08-27       Impact factor: 5.482

View more
  36 in total

1.  A systematic review of the impact of contemporary treatment modalities for cervical cancer on women's self-reported health-related quality of life.

Authors:  L M Wiltink; M King; F Müller; M S Sousa; M Tang; A Pendlebury; J Pittman; N Roberts; L Mileshkin; R Mercieca-Bebber; M-A Tait; R Campbell; C Rutherford
Journal:  Support Care Cancer       Date:  2020-06-18       Impact factor: 3.603

2.  Coping and psychological distress in young adults with advanced cancer.

Authors:  Kelly M Trevino; Paul K Maciejewski; Karen Fasciano; Joseph Greer; Ann Partridge; Elizabeth L Kacel; Susan Block; Holly G Prigerson
Journal:  J Support Oncol       Date:  2012-01-29

3.  A core competency framework for prostate cancer peer navigation.

Authors:  P K Flora; J L Bender; A S Miller; L Parvin; S Soheilipour; N Maharaj; E Milosevic; A Matthew; A Kazanjian
Journal:  Support Care Cancer       Date:  2019-10-15       Impact factor: 3.603

4.  Screening for sexual health concerns in survivors of gynecological cancer.

Authors:  Karen Roberts; Travis Chong; Emma Hollands; Jason Tan; Ganendra Raj Kader Ali Mohan; Paul A Cohen
Journal:  Support Care Cancer       Date:  2019-05-18       Impact factor: 3.603

5.  Assessing quality of life in patients after partial laryngectomy.

Authors:  F Hebel; K Mantsopoulos; C Bohr
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

6.  Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.

Authors:  N D Fleming; P T Ramirez; P T Soliman; K M Schmeler; G B Chisholm; A M Nick; S N Westin; M Frumovitz
Journal:  Gynecol Oncol       Date:  2016-10-11       Impact factor: 5.482

7.  Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer.

Authors:  P Harter; I Schrof; L M Karl; R Hils; V Kullmann; A Traut; H Scheller; A du Bois
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

8.  Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study.

Authors:  Jeanne Carter; Helen Huang; Dana M Chase; Joan L Walker; David Cella; Lari Wenzel
Journal:  Int J Gynecol Cancer       Date:  2012-11       Impact factor: 3.437

9.  Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer.

Authors:  Kelly M Trevino; Karen Fasciano; Holly G Prigerson
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

10.  Assessment of sexual activity and dysfunction in medically underserved women with gynecologic cancers.

Authors:  Andrea Bradford; Bryan Fellman; Diana Urbauer; Jessica Gallegos; Kristen Meaders; Celestine Tung; Lois Ramondetta
Journal:  Gynecol Oncol       Date:  2015-08-29       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.